Ichnos Glenmark Innovation (IGI) Elevates Mario Perro, Ph.D., as Chief Scientific Officer

Ichnos Glenmark Innovation, Inc. (IGI), a global, fully integrated clinical-stage biotechnology company focused on developing multispecifics™ in oncology announced the promotion of Mario Perro, Ph.D., to the new position of Chief Scientific Officer.

"Mario is a rare blend of scientific depth and operational rigor. Under his leadership, IGI is advancing our BEAT® multispecifics pipeline with speed, clarity, and clinical purpose and the next wave of NK-cell engagers IMMUNITE ™ and T-cell engagers for solid tumors" said Dr. Cyril Konto, IGI's President, Executive Director and Chief Executive Officer. "His promotion to Chief Scientific Officer positions us to convert cutting-edge immunology into meaningful patient outcomes and durable value for our stakeholders".

Dr. Perro joined Ichnos Sciences in 2021 and most recently served as IGI's Head of Research. He has played a key role in the development of next-generation immunotherapies based on IGI's BEAT® platform. With more than 10 years of experience in the biopharma sector and a strong focus on understanding the activation, regulation, and genetic engineering of lymphocytes, Dr. Perro has made significant contributions in drug discovery and development utilizing molecular biology, preclinical models, and advanced imaging tools.

About IGI

IGI is a global, fully integrated clinical-stage biotechnology company focused on developing innovative biologics in oncology. Headquartered in New York, NY, IGI is advancing a robust pipeline of novel, first-in-class multispecifics™ aimed at addressing complex diseases and treating patients holistically. Powered by its proprietary BEAT® technology platform, IGI is committed to delivering breakthrough, curative therapies to improve and extend the lives of patients battling hematological malignancies and solid tumors. For more information, visit www.IGInnovate.com.

IGI Corporate Communications
Corporate.communications@IGInnovate.com